台灣臨床試驗主持人資料庫|TPIDB

TPIDB > Principal Investigator

Principal Investigator

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Urology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2025-09-17

林家齊Lin, Chia-Chi

Principal Investigator

Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

371Cases

Profile Clinical Trials List Publication

Highlights

I have established one of the largest oncology phase I centers in Asia for more than 10 years. I played a very important role in developing novel chemotherapies, e.g. TLC388 (topoisomerase I inhibitor), trastuzumab deruxtecan (DS8201, anti-HER2 antibody drug conjugate); and targeted therapies, e.g. volasertib (BI6727, polo-like kinase inhibitor), xentuzumab (BI836845, anti-IGF antibody), BI853520 (FAK inhibitor), vismodegib (LDE225, SMO inhibitor), osimertinib (AZD9291, EGFR inhibitor), TSR011 (ALK inhibitor), plexidartinib (PLX3397, CSF1R inhibitor). In recent years, we were also heavily involved in developing novel immunotherapies, e.g. pembrolizumab (MK3475, anti-PD1 antibody) in head and neck cancer, gastric cancer; spartalizumab (PDR001, anti-PD1 antibody) in malignant melanoma, non-small cell lung cancer, anaplastic thyroid cancer; spartalizumab (PDR001, anti-PD1 antibody) + MBG453 (anti-TIM3 antibody) in malignant melanoma, non-small cell lung cancer; tislelizumab (BGB-A317, anti-PD1 antibody) in non-small cell lung cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma; LY3300054 (anti-PD-L1 antibody) + LY3321367 (anti-TIM3 antibody) in MSI high colorectal cancer; bintrafusp alpha (MSB0011359C, anti-PD-L1 antibody + TGFβ trap); durvalumab (MEDI4736, anti-PD-L1 antibody) + ramucirumab (IMC1121B, anti-VEGFR antibody) in non-small cell lung cancer, gastric cancer, hepatocellular carcinoma.

Study Area

Early clinical trial of new drugs for cancers
Chest cancer (esophageal cancer, lung cancer)
Pharmacotherapy of urinary cancer (bladder cancer, prostate cancer, kidney cancer)

Professional Experiences

National Taiwan University

Professor

Graduate Institute of Clinical Medicine

National Taiwan University

Attending Physician

Division of Medical Oncology, Department of Oncology

Education

National Taiwan University

Graduate Institute of Clinical Medicine, College of Medicine

Ph.D.

National Taiwan University

School of Medicine, College of Medicine

M.D.

Clinical Trials List

See All681Cases

2016

Total 681

I 187
I/II 72
II 134
II/III 21
III 241
IV 2
Others 24

Number of Studies by Scale

26件

Taiwan Multiple Center

Taiwan Single Center

11Cases

Taiwan Multiple Center

26Cases

Multi-Regional Multi-Center

716Cases